H eavy menstrual bleeding (HMB) is one of the most common reasons for primary care consultations by women of reproductive age. The condition is associated with a reduction in health-related quality of life and substantial utilisation of health service resources. There are several underlying causes of HMB, which are generally benign in nature and can exist in isolation or in combination. The majority of women presenting with HMB can be managed in primary care, either expectantly or using effective medical treatments. Referral to secondary care should be restricted to refractory cases, where surgical or radiological interventions may be indicated and where pre-malignant or malignant uterine disease is suspected. This article will explore the nature of HMB, the terminology that should be used to describe menstrual disorders and the aetiology of HMB. Diagnostic work-up and clinical management, encompassing treatment in primary care and indications for referral to secondary care based on national clinical guidance, will also be discussed.
The GP curriculum and heavy menstrual bleeding Clinical module 3.06: Women's health covers all areas of women's health. The following domains are of particular relevance to this article on heavy menstrual bleeding where a GP is expected to be able to:
. Integrate the fact that many women consult for lifestyle advice and that you as a GP should not over-medicalise these issues . Demonstrate an understanding of the importance of risk factors in the diagnosis and management of women's problems . Recognise common signs and symptoms of, and know how to manage, gynaecological disease . Demonstrate knowledge of women's health problems, conditions and diseases . Be familiar with and implement the key national guidelines that influence healthcare provision for women's problems Menstruation, menses, menstrual period and period are used synonymously and refer to a woman's monthly bleeding from the uterus via the vagina. The menstrual loss consists of blood, glandular secretions and endometrial tissue. The cyclical bleeding occurs in response to cyclical changes in hormonal activity. The 17b-oestradiol produced from follicles within the ovary stimulates the endometrium to proliferate. Following ovulation, the corpus luteum within the ovary produces progesterone in addition to oestrogen to prepare endometrium for implantation. In the absence of pregnancy, the corpus luteum stops producing progesterone and this 'progesterone withdrawal' precipitates shedding of the superficial endometrial lining. Irregular cycles are often the result of anovulation, where regular production of progesterone is lacking. It is for this reason that cyclical progestogens alone or as part of the combined oral contraceptive pill are effective in regulating menstrual bleeding.
bleeding should be defined as 'excessive menstrual blood loss which interferes with the woman's physical, emotional, social and material quality of life, and which can occur alone or in combination with other symptoms'. It is important to note that the term 'menorrhagia' should no longer be used and the more understandable term heavy menstrual bleeding (HMB) used instead (Munro, Critchley, & Fraser, 2012 (Hallberg, Hogdahl, Nilsson, & Rybo, 1966) . Clearly, objective measurement has no practical application in clinical practice; however, semi-objective measures are available. These can range from a simple enquiry as to the severity of bleeding e.g. 'flooding' through sanitary protection or clothing, the quantity and type of sanitary protection, or the use of pictorial charts (where women estimate blood loss based on the coverage of standard tampons or sanitary towels). The latter measure, known as a Pictorial Blood Assessment Chart (Higham, O'Brien, & Shaw, 1990; Janssen, Scholten, & Heintz, 1995) are generally restricted to use in clinical trials to estimate blood loss; however, electronic versions and related 'apps' can be downloaded to smart phones and some patients may find these a useful way of recording their symptoms. The main message is, however, to ascertain how the bleeding affects a woman's daily life rather than to quantify it. Excessive menstrual bleeding will impact in a number of life domains, including social, emotional, sexual, physical and professional (Clark et al., 2002) . The impact of her symptoms will vary depending not only on the individual but also on external factors, e.g. women in male-dominated work places or in highly visible jobs, or where access to toilets is limited, may be less tolerant of heavy or unpredictable bleeding and seek medical help and advice earlier.
The aforementioned definition of HMB also emphasises the prevalence of other highly relevant and associated menstrual symptoms. These can include cycle irregularity, prolonged bleeding, frequent scheduled bleeding, 'breakthrough' intermenstrual bleeding (IMB), menstrual pain, physical and mental pre-menstrual or perimenopausal symptoms. An efficient menstrual history should capture these associated symptoms, as this will help diagnose the most likely underlying pathologies and aid selection of the most appropriate treatments. For example, severe, prolonged cyclical menstrual pain may indicate the presence of adenomyosis or endometriosis.
Post-coital bleeding (PCB) is generally suggestive of cervical pathology. However, some women with HMB, especially those where cycles are irregular or IMB is present, may complain of PCB. This probably represents endometrial shedding or release of contained blood and debris within the uterus triggered by coitus rather than the presence of a cervical lesion, but a pelvic examination including visual inspection of the cervix would be indicated in such women. Fertility and contraceptive wishes are also important to ascertain from the outset, as many medical and surgical treatment choices are either contraceptive or preclude future fertility.
What causes HMB? The aetiology of HMB is still much debated, but in recent times attempts have been made to standardise nomenclature (Table 1 ) (Munro et al., 2012) . In general, most women do not have any recognisable uterine pathology and the HMB is thought to reflect disturbances of local endometrial haemostasis e.g. deficiencies in local production of vasoconstrictors, such as prostaglandin F2a (Gleeson, 1994 ). This has been described in text books as 'dysfunctional uterine bleeding'. The second-mostlikely cause of HMB is uterine fibroids (leiomyomas), which are benign tumours of smooth muscle and connective tissue. Fibroids can be confined to the uterine muscle (intramural), extend into the serosa (subserosal) or into the endometrial cavity (submucosal). Fibroids are detected in approximately 40% of women, but not all are clinically significant (Owen and Armstrong, 2015) . The larger the fibroid mass (size and multiplicity), then the greater is the likelihood of menstrual problems, as well as . The 'PALM' group consists of discrete (structural) entities that can be measured visually with imaging techniques and/or histopathology, whereas the COEIN group is related to non-structural entities that are not deEned by imaging or histopathology. pressure or 'bulk' symptoms. These include abdominal distension, bladder symptoms (e.g. urinary frequency, incomplete voiding and urinary retention), bowel symptoms (e.g. incomplete evacuation, constipation) and even respiratory symptoms (e.g. breathlessness) (Coyne, Margolis, Murphy, & Spies, 2012) . Submucosal fibroids, which distort the uterine cavity, are thought to be particularly significant in the causation of HMB ( Fig. 1 ) (Munro et al., 2012) .
Other potential structural causes of HMB are less common, they include uterine polyps, adenomyosis and endometrial disease (Table 1) . Adenomyosis refers to the presence of endometrial glands and stroma within the myometrium. This ectopic endometrial tissue will respond to cyclic hormonal changes and is thought to contribute to increased uterine volume, pain and bleeding. Transvaginal ultrasound (TVS) reports are increasingly highlighting the presence of adenomyosis based upon certain sonographic features thought to be characteristic, although the diagnostic accuracy of TVS is modest compared with the gold standard histological diagnosis following examination of the myometrium from a hysterectomy specimen (Meredith, Sanchez-Ramos, & Kaunitz, 2009 ). The role of polyps in causation of HMB needs more evaluation, given the relatively high prevalence in asymptomatic and subfertility populations (Cooper et al., 2015) . Endometrial cancer is uncommon in women of reproductive age, but its potential precursor, endometrial hyperplasia, is more prevalent, especially around the peri-menopause where anovulatory cycles leading to unopposed oestrogenic endometrial proliferation are more common.
Of the non-structural causes of HMB ( , 2007) suggests that an examination should be undertaken when a 'structural or histological abnormality is possible' or when a trial of medical treatment fails. However, the clinical history is not particularly discriminatory for the detection of the presence of structural or histological pathology. Thus, unless the woman does not wish to be examined, a pelvic examination to include visual inspection of the cervix and an assessment of the size, mobility and tenderness of the uterus is useful. The presence of abnormal features on examination, such as a pelvic mass of uncertain origin or considered to be a uterus beyond 12 weeks size, uterine fixity and significant tenderness should trigger referral for a TVS and consideration of the need for referral to secondary care (Table 2) . Women with risk factors for endometrial hyperplasia (Table 2) , or symptoms suspicious of cancer, such as irregular bleeding, should be referred to secondary care for an endometrial biopsy and/or hysteroscopy. Although endometrial hyperplasia has traditionally been considered pre-malignant, a recent a review of the natural history suggests the risk of progression untreated to endometrial cancer is less than 3%. However, where cytological atypia is present this risk is estimated to rise to 30% (Norris, Connor, & Kurman, 1986) . Table 3 . In the first instance, reassurance about the absence of serious pathology, stating that it is a common complaint that affects many women and an explanation of why HMB and related symptoms occur may be all that is required. However, most women will find their symptoms burdensome and seek treatment. The NICE HMB guideline (National Collaborating Centre for Women's and Children's Health, 2007) recommends the levonorgestrel-releasing intrauterine system (LNG-IUS -Mirena, Bayer HealthCare) as firstline medical treatment in HMB, based on prevailing evidence of its superiority in reducing blood loss compared with available non-hormonal and hormonal medical treatments (Stewart, Cummins, Gold, Jordan, & Phillips, 2001) . Women should be counselled about the likelihood of erratic bleeding during the initial months of use. Since publication of this guideline, a randomised controlled trial (RCT) of 571 women with HMB in primary care has been conducted. Women were allocated either the LNG-IUS or one of the other NICE-recommended medical treatments, namely tranexamic acid, mefenamic acid, combined oestrogen progestogen or progesterone alone). The RCT found that the LNG-IUS was more effective in reducing the effect of HMB on quality of life at 6 months, and these effects were maintained at 2-year follow-up (Gupta, Shina, Lumsden, & Hickey, 2013) .
The safety and effectiveness of the LNG-IUS in treating the symptom of HMB does not negate consideration of the potential causes of HMB. Local intrauterine progestogens will down-regulate oestrogen and progesterone receptors in the uterus, thereby rendering the endometrium atrophic (Apter, Gemzell-Danielsson, Hauck, Rosen, & Zurth, 2014) thereby combating most underlying causes of HMB listed in Table 1 . Indeed it should be particularly effective in reversing bleeding considered to be of endometrial origin, adenomyosis and endometrial hyperplasia. However, the efficacy of the LNG-IUS where the uterine cavity is enlarged by adenomyosis or fibroids or the presence of submucosal fibroids may be reduced (Magalhães, Aldrighi, & de Lima, 2007 Indeed, the RCT referred to above supporting the use of the LNG-IUS excluded women where fibroids were suspected, due to the uterine size being greater than a gravid uterus of 10-12 week size (Gupta et al., 2013) . Furthermore, many women may be reluctant to accept or tolerate hormonal treatment (even though locally acting, progestogen is absorbed into the bloodstream), feel comfortable with a 'foreign body', or experience adverse effects such as erratic bleeding and discharge. Indeed, the 2-year continuation of treatment with the LNG-IUS is around 60-70% (Gupta et al., 2013; Hurskainen et al., 2001) . The contraceptive effect of the LNG-IUS will be advantageous for many women, but not those wishing to conceive. Thus, the LNG-IUS should not be considered a panacea. However, in general terms the LNG-IUS will be an appropriate first-line medical treatment for women presenting to their GP with HMB regardless of underlying cause.
This contrast with the situation in secondary care, where women referred refractory to the LNG-IUS require additional uterine evaluation in the form of either a TVS, an endometrial biopsy and/or an outpatient hysteroscopy to further elucidate the underlying pathologies and tailor treatment, which will usually be uterine sparing surgical/radiological interventions. These include hysteroscopic polypectomy to remove uterine polyps under direct vision using miniature electrosurgical or mechanical instruments (Cooper et al., 2015; Smith, Middleton, Connor, & Clark, 2014) . Hysteroscopic myomectomy to remove submucosal fibroids also employs endoscopic mechanical and electrosurgical instruments, but these are of a larger diameter compared with those used for polypectomy, and the procedures require general anaesthesia (Emanuel, Wamsteker, Hart, Metz, & Lammes, 1999) . Endometrial ablation treats dysfunctional uterine bleeding (Smith, Malick, & Clark, 2014) and utilises a variety of semi-automated intrauterine devices that impart thermal energy (e.g. hot fluid balloons, cryotherapy, and microwave and radiofrequency electrical energy) to ablate the basal endometrium. Intramural and subserosal uterine fibroids can be removed laparoscopically or via laparotomy (i.e. laparoscopic or open myomectomy) (Stewart, 2015) . Uterine artery embolisation is a non-surgical radiological alternative to treat uterine fibroids (Gupta et al., 2014) and is particularly useful in those women where the risk of surgical morbidity is increased. Hysterectomy is still widely performed, and is the most-effective therapy, guaranteeing amenorrhoea. The vaginal and laparoscopic routes are increasingly being adopted over laparotomy, in an attempt to reduce surgical morbidity and speed recovery times (Aarts et al., 2015) .
Other pharmacological treatment options are available to women when the LNG-IUS is unacceptable, not tolerated, ineffective or contraindicated. These include nonhormonal options; the anti-fibrinolytic drug tranexamic acid or the prostaglandin synthetase inhibitors (nonsteroidal anti-inflammatory agents (NSAIDs)) and hormo-nal treatments, namely the combined oral contraceptives and systemic progestogens. Tranexamic acid is more effective than NSAIDs in reducing HMB, and should be preferred unless HMB coexists with menstrual pain where NSAIDs alone or in combination with tranexamic acid should be used. These agents are recommended for as long as they are found to be beneficial, but they should be stopped if it does not improve symptoms within three menstrual cycles (www.nice.org/uk/ CG044). The combined oral contraceptive helps prevent endometrial over-proliferation, thereby minimising menstrual loss, regulates cycles and can treat menstrual and non-menstrual pelvic pain, making it a highly useful intervention. The oral progestogen norethisterone actetate (15 mg) can be prescribed daily from days 5 to 26 of the menstrual cycle, it helps suppress the endometrium and regulate cycles, but long term use is contentious due to its side-effect profile. Injected long-acting progestogens may also be useful, although as with the prescription of the LNG-IUS, women should be warned about prolonged, unscheduled genital tract bleeding initially. The published UK medical eligibility criteria for contraceptive use should be considered before prescribing hormonal medications for the treatment of HMB (Faculty of Sexual and Reproductive Health, 2009).
In addition to the medical treatments covered by NICE, the recent introduction of the selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA -Esyma, Gedeon Richter UK) needs to be appreciated. This group of pharmaceutical agents has the potential to revolutionise future gynaecological practice, because they have the potential to treat HMB, shrink uterine fibroids, provide reversible contraception, and treat pre-menstrual syndrome, chronic pelvic pain and endometriosis. Two recent RCTs have demonstrated the benefit of UPA in reducing the volume of fibroids (Donnez et al., 2012a; Donnez et al., 2012b) and the quantity of menstrual bleeding prior to surgery without inducing a menopausal state, as is the case with gonadotrophin-releasing hormone analogues. Longer-term studies are required to support the safety and ongoing efficacy of UPA in fibroid-associated HMB. In light of this evidence, further interest has arisen in the mechanism of action of these SPRMs, such that a multi-centre trial has just started comparing the use of UPA against the current 'gold standard' treatment of LNG-IUS with a mechanistic examination of endometrial biopsies and functional magnetic resonance imaging (UCON trial http://public.ukcrn.org.uk/search/StudyDetail.aspx? StudyID¼18534).
Key points
. ......................................................................................................................................................................................................... irregularity, pre-menstrual symptoms and pain in order to improve health-related quality of life . Cycle regularity is a key feature of the menstrual history; regular cycles are indicative of ovulation and are not associated with endometrial disease and may respond to non-hormonal treatments such as tranexamic acid or NSAIDs; in contrast, women with irregular cycles are at higher risk of endometrial hyperplasia and polyps and will require hormonal or surgical treatment to regulate, reduce or stop bleeding . Iron-deficiency anaemia in women with HMB is highly correlated with the presence of significant uterine fibroids, and earlier referral is indicated as these women are more likely to be refractory to standard pharmacological treatments . Pelvic examination, although not mandatory at initial presentation, can provide valuable information that can influence further management; exclusion of cervical cancer, delineation of uterine size, identification of pelvic masses and uterine immobility suggestive of adhesions arising from conditions such as endometriosis and past pelvic infection . Referral to secondary care is generally indicated when pelvic examination is abnormal (mass, uterine fixity and tenderness), when initial medical treatment is ineffective, or where risk factors for endometrial disease are suspected . The LNG-IUS should be considered first-line therapy, as it is the most-effective medical treatment
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